← All trials
NCT05324124
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2022
- Primary completion
- Jun 22, 2022
- Completion date
- Jun 22, 2022
- First posted
- Apr 12, 2022
- Last posted
- Jul 13, 2022
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Loxo OncologyLead sponsor
- Eli LillyCollaborator
- Eli LillyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.